Standard BioTools Inc. received a formal warning from Nasdaq on July 22, 2026, after its shares traded below $1.00 for 30 consecutive business days. The Boston-based company, which lists its common stock on the Nasdaq Global Select Market under the ticker LAB, now has until January 19, 2027 to bring its share price back above that threshold.
What a delisting notice actually means
A Nasdaq minimum bid price notice is not a removal order. It is the exchange's way of putting a company on a formal clock. Nasdaq Listing Rule 5450(a)(1) requires that every stock on the Global Select Market maintain a closing bid price at or above $1.00 per share. When a stock stays below that level for 30 consecutive business days, Nasdaq's Listing Qualifications Department issues a notice and an automatic 180-day window opens.
During that window, the stock keeps trading normally. Standard BioTools said the notice has no immediate effect on its listing, its trading, or its reporting obligations to the Securities and Exchange Commission. Shareholders can still buy and sell LAB shares on Nasdaq without interruption.
The 180-day clock and what comes next
The company has until January 19, 2027 to satisfy the minimum bid price rule for at least 10 consecutive business days. That is the stated target the filing sets out.
If it cannot meet that deadline, a second path exists. Standard BioTools could transfer its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, which carries different requirements. That transfer would require an application fee, written notice to Nasdaq staff, and proof that the company meets the Capital Market's initial listing standards in every category except the minimum bid price. In exchange, the company could qualify for a second 180-day compliance period.
One mechanism the filing names explicitly as a potential remedy: a reverse stock split. A reverse split reduces the number of shares outstanding and proportionally raises the per-share price, which can clear the $1.00 bar without any change to the company's underlying value.
What the filing does not say
The 8-K, signed by Chief Financial Officer Alex Kim and dated July 24, 2026, offers no assurance that Standard BioTools will regain compliance, and no specific plan beyond stating an intention to work toward it within the prescribed timeframe.